Amphotericin B formulations variably enhance antifungal activity of human neutrophils and monocytes against Fusarium solani: Comparison with Aspergillus fumigatus

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 4, 2008, Pages 810-817

  Dotis, John ^a   Simitsopoulou, Maria ^a,b   Dalakiouridou, Maria ^a   Konstantinou, Thomai ^a   Panteliadis, Christos ^a   Walsh, Thomas J ^c   Roilides, Emmanuel ^a,c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ALEXANDER TECHNOLOGICAL EDUCATIONAL INSTITUTE OF THESSALONIKI   (Greece)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Filamentous fungi; Hyphal damage; Oxidative burst; Phagocytes

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CYTOCHROME C; HYDROGEN PEROXIDE; SUPEROXIDE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; CELL VIABILITY; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG FORMULATION; FUNGUS HYPHAE; FUSARIUM SOLANI; HOST RESISTANCE; HUMAN; HUMAN CELL; IMMUNOMODULATION; MONOCYTE; NEUTROPHIL; NONHUMAN; PHAGOCYTE; RESPIRATORY BURST;

ADULT; AMPHOTERICIN B; ASPERGILLUS FUMIGATUS; DRUG COMBINATIONS; FUSARIUM; HUMANS; HYPHAE; IMMUNOLOGIC FACTORS; MONOCYTES; NEUTROPHILS; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; REACTIVE OXYGEN SPECIES; RESPIRATORY BURST; TETRAZOLIUM SALTS;

EID: 41149170259     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn036     Document Type: Article

References (33)

1. Brakhage AA. Systemic fungal infections caused by Aspergillus species: Epidemiology, infection process and virulence determinants. Curr Drug Targets 2005; 6: 875-86.
2. Clark TA, Hajjeh RA. Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis 2002; 15: 569-74.
3. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years' experience at a cancer center and implications for management. Blood 1997; 90 999-1008.
4. Wheat LJ, Goldman M, Sarosi G. State-of-the-art review of pulmonary fungal infections. Semin Respir Infect 2002; 17: 158-81.
5. Dignani MC, Anaissie E. Human fusariosis. Clin Microbiol Infect 2004; 10 Suppl 1: 67-75.
6. Fleming RV, Walsh TJ, Anaissie EJ. Emerging and less common fungal pathogens. Infect Dis Clin North Am 2002; 16: 915-33, vi-vii.
7. Antachopoulos C, Roilides E. Cytokines and fungal infections. Br J Haematol 2005; 129: 583-96.
8. Shoham S, Levitz SM. The immune response to fungal infections. Br J Haematol 2005; 129: 569-82.
9. Babior BM. Phagocytes and oxidative stress. Am J Med 2000; 109 33-44.
10. Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother 2002; 49 Suppl 1: 31-6.
11. Simitsopoulou M, Roilides E, Dotis J et al. Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B. Antimicrob Agents Chemother 2005; 49: 1397-403.
12. Dotis J, Simitsopoulou M, Dalakiouridou M et al. Effects of lipid formulations of amphotericin B on activity of human monocytes against Aspergillus fumigatus. Antimicrob Agents Chemother 2006; 50: 868-73.
13. Perkhofer S, Blum G, Speth C et al. Influence of amphotericin B and amphotericin B colloidal dispersion on the functions of human phagocytes in defence against Aspergillus species. Eur J Clin Microbiol Infect Dis 2007; 26: 413-7.
14. Boucher HW, Groll AH, Chiou CC et al. Newer systemic antifungal agents: Pharmacokinetics, safety and efficacy. Drugs 2004; 64 1997-2020.
15. Groll AH, Lyman CA, Petraitis V et al. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations. Antimicrob Agents Chemother 2006; 50: 3418-23.
16. Roilides E, Kadiltsoglou I, Dimitriadou A et al. Interleukin-4 suppresses antifungal activity of human mononuclear phagocytes against Candida albicans in association with decreased uptake of blastoconidia. FEMS Immunol Med Microbiol 1997; 19: 169-80.
17. Meshulam T, Levitz SM, Christin L et al. A simplified new assay for assessment of fungal cell damage with the tetrazolium dye, (2,3)-bis-(2-methoxy-4-nitro-5-sulphenyl)-(2H)-tetrazolium-5-carboxanil ide (XTT). J Infect Dis 1995; 172: 1153-6.
18. Gil-Lamaignere C, Roilides E, Maloukou A et al. Amphotericin B lipid complex exerts additive antifungal activity in combination with polymorphonuclear leucocytes against Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother 2002; 50: 1027-30.
19. Kuthan H, Ullrich V, Estabrook RW. A quantitative test for superoxide radicals produced in biological systems. Biochem J 1982; 203 551-8.
20. Tsistsigiannis DI, Bok JW, Andes D et al. Aspergillus cyclooxygenase-like enzymes are associated with prostaglandin production and virulence. Infect Immun 2005; 73: 4548-59.
21. Winn RM, Gil-Lamaignere C, Maloukou A et al. Interactions of human phagocytes with moulds Fusarium spp. and Verticillium nigrescens possessing different pathogenicity. Med Mycol 2003; 41: 503-9.
22. Sau K, Mambula SS, Latz E et al. The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. J Biol Chem 2003; 278: 37561-8.
23. Bellocchio S, Gaziano R, Bozza S et al. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4. J Antimicrob Chemother 2005; 55: 214-22.
24. Gersuk GM, Underhill DM, Zhu L et al. Dectin-1 and TLRs permit macrophagesto distinguish between different Aspergillus fumigatus cellular states. J Immunol 2006; 176: 3717-24.
25. Kaur S, Gupta VK, Thiel S et al. Protective role of mannan-binding lectin in a murine model of invasive pulmonary aspergillosis. Clin Exp Immunol 2007; 148:382-9.
26. Wilson E, Thorson L, Speert DP. Enhancement of macrophage superoxide anion production by amphotericin B. Antimicrob Agents Chemother 1991; 35: 796-800.
27. Sullivan GW, Carper HT, Mandell GL. Lipid complexing decreases amphotericin B inflammatory activation of human neutrophils compared with that of a desoxycholate-suspended prepiration of amphotericin B (Fungizone). Antimicrob Agents Chemother 1992; 36: 39-45.
28. Roilides E, Walsh TJ, Rubin M et al. Effects of antifungal agents on the function of human neutrophils in vitro. Antimicrobial Agents and Chemotherapy 1990; 34: 196-201.
29. Marmer DJ, Fields BT, Jr, France GL et al. Ketoconazole, amphotericin B, and amphotericin B methyl ester: Comparative in vitro and in vivo toxicological effects on neutrophil function. Antimicrob Agents Chemother 1981; 20: 660-5.
30. Carreras MC, Riobo NA, Pargament GA et al. Effects of respiratory burst inhibitors on nitric oxide production by human neutrophils. Free Radic Res 1997; 26: 325-34.
31. Villamor E, Kessels CG, Fischer MA et al. Role of superoxide anion on basal and stimulated nitric oxide activity in neonatal piglet pulmonary vessels. Pediatr Res 2003; 54: 372-81.
32. Diamond RD, Clark RA. Damage to Aspergillus fumigatus and Rhizopus oryzae hyphae by oxidative and nonoxidative microbicidal products of human neutrophils in vitro. Infect Immun 1982; 38 487-95.
33. Rex JH, Bennett JE, Gallin JI et al. Normal and deficient neutrophils can cooperate to damage Aspergillus fumigatus hyphae. J Infect Dis 1990; 162: 523-8.